CalciMedica, Inc. (NASDAQ:CALC) Insider Eric W. Roberts Buys 5,000 Shares

CalciMedica, Inc. (NASDAQ:CALC) insider Eric W. Roberts acquired 5,000 shares of the stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average price of $3.22 per share, with a total value of $16,100.00. Following the completion of the purchase, the insider now owns 10,223 shares in the company, valued at $32,918.06. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

CalciMedica Trading Up 25.7 %

CALC stock opened at $3.96 on Friday. The business’s 50-day moving average price is $5.26 and its two-hundred day moving average price is $4.60. CalciMedica, Inc. has a 1-year low of $1.75 and a 1-year high of $8.38.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. As a group, analysts expect that CalciMedica, Inc. will post -2.05 earnings per share for the current year.

Wall Street Analyst Weigh In

CALC has been the subject of several analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 target price on shares of CalciMedica in a report on Monday, April 1st. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of CalciMedica in a report on Thursday.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Meritage Portfolio Management increased its holdings in shares of CalciMedica by 360.0% during the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after buying an additional 36,000 shares in the last quarter. BML Capital Management LLC increased its holdings in CalciMedica by 63.8% in the fourth quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock valued at $416,000 after purchasing an additional 56,643 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new stake in CalciMedica in the third quarter valued at $432,000.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.